非酒精性单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学比较*

doi:10.3969/j.issn.1672-5069.2022.02.016

摘要/Abstract

摘要： 目的分析比较非酒精性单纯性脂肪肝(NAFL)与非酒精性脂肪性肝炎(NASH)患者血清脂质组学差异。方法 2015年5月～2020年5月我院诊治的NAFL患者107例和NASH患者92例,采用超高效液相色谱-串联质谱法进行血清脂质组学分析。结果与NAFL组比,NASH组有3种游离脂肪酸(FFA,12:0、18:1和20:0)、2种二酰甘油(DAG,36:3和36:4)、16种三酰甘油(TAG,52:4、52:5、54:4、54:5、54:8、56:5、56:7、56:8、56:9、58:4、58:8、58:9、58:10、58:11、60:6和60:12)、2种磷脂酰胆碱(PC,36:5和38:6)、1种磷脂酰丝氨酸(PS,33:0)、2种溶血磷脂酰乙醇胺(LPE,36:2和39:1)、2种胆固醇脂(CE,20:4和22:6)、4种鞘磷脂(SM,36:3、38:2、40:1和42:1)、3种神经酰胺(Cer,40:1、41:1和42:1)水平升高,3种FFA(16:1、22:4和22:5)、1种TAG(54:2)、3种PC(32:1、35:4和38:3)、5种磷脂酰肌醇(PI,32:1、34:1、34:2、36:4和40:4)、5种缩醛磷脂酰胆碱(PlsCho,34:2、36:2、36:4、40:5和42:5)、7种缩醛磷脂酰乙醇胺(PlsEtn,36:6、38:5、38:6、38:7、40:7、40:8和42:7)水平降低(P<0.05)。结论 NAFL和NASH患者血清脂质代谢存在明显差异,通过血清脂质组学分析可进一步明确不同分型非酒精性脂肪性肝病患者脂质代谢特征。

关键词: 非酒精性单纯性脂肪肝, 非酒精性脂肪性肝炎, 脂质组学, 超高效液相色谱-串联质谱分析

Abstract: Objective The aim of this study was to analyze serum lipidomics of patients with non-alcoholic simple fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Methods 107 patients with NAFL and 92 patients with NASH were enrolled in our hospital between May 2015 and May 2020. The basic data were collected, and serum lipidomics were analyzed by ultra-high performance liquid chromatography-tandem mass spectrometry. Results Compared with in NAFL group, the levels of 3 kinds of free fatty acids (FFA, 12:0, 18:1 and 20:0), 2 kinds of diacylglycerols (DAG, 36:3 and 36:4), 16 kinds of triacylglycerols (TAG, 52:4, 52: 5, 54: 4, 54: 5, 54: 8, 56: 5, 56: 7, 56: 8, 56: 9, 58: 4, 58: 8, 58: 9, 58: 10, 58 : 11, 60: 6 and 60: 12), 2 kinds of phosphatidylcholines (PC, 36:5 and 38:6), 1 phosphatidylserine (PS, 33:0), 2 kinds of lysophosphatidyl ethanolamines (LPE, 36:2 and 39:1), 2 kinds of cholesterol esters (CE, 20:4 and 22:6, 4 kinds of sphingomyelins (SM, 36:3, 38:2, 40:1 and 42:1) and 3 kinds of ceramides (Cer, 40:1, 41:1 and 42:1) increased in NASH group, while 3 kinds of FFA (16: 1, 22: 4 and 22: 5), 1 TAG (54: 2), 3 types of PC (32:1, 35:4 and 38:3), 5 types of phosphatidylinositols (PI, 32:1, 34:1, 34:2, 36:4 and 40:4), 5 kinds of phosphatidalcholines (PlsCho, 34:2, 36:2, 36:4, 40:5 and 42:5) and 7 kinds of phosphatidal ethanolamines (PlsEtn, 36:6, 38:5, 38:6, 38:7, 40:7, 40:8 and 42:7) levels decreased (P<0.05). Conclusion There is a significant difference in serum lipid metabolism between patients with NAFL and patients with NASH, which might be help clarify the pathogenesis of patients with non-alcoholic simple fatty liver diseases.

Key words: Non-alcoholic steatohepatitis, Non-alcoholic simple fatty liver, Lipidomics, Ultra-high performance liquid chromatography-tandem mass spectrometry

王琳, 林雪松, 丁楠. 非酒精性单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学比较^*[J]. 实用肝脏病杂志, 2022, 25(2): 215-218.

Wang Lin, Lin Xuesong, Ding Nan. Serum lipidomics in patients with non-alcoholic simple fatty liver and non-alcoholic steatohepatitis[J]. Journal of Practical Hepatology, 2022, 25(2): 215-218.

参考文献

[1] Fazel Y, Koenig AB, Sayiner M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism, 2016, 65(8):1017-1025.
[2] 谢晓.无创诊断和评估非酒精性脂肪性肝炎研究进展.实用肝脏病杂志,2019, 22(2):301-304.
[3] Marengo A, Jouness RI, Bugianesi E, et al. Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis, 2016, 20(2):313-324.
[4] Castera L, Friedrich-Rust M, Loomba R. Noninvasiveassessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156(5):1264-1281.
[5] Draijer LG, Froon-Torenstra D, van Weeghel M, et al. Lipidomics in nonalcoholic fatty liver disease: Exploring serum lipids as biomarkers for pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr, 2020, 71(4):433-439.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[7] Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond), 2018, 18(3):245-250.
[8] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci,2019, 76(1):99-128.
[9] Simon J, Ouro A, Ala-Ibanibo L, et al. Sphingolipids innon-alcoholic fatty liver disease and hepatocellular carcinoma: Ceramide turnover. Int J Mol Sci, 2019, 21(1):40-51.
[10] Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, et al. New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci, 2018, 19(7):2034-2055.
[11] Mato JM, Alonso C, Noureddin M, et al. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol, 2019, 25(24):3009-3020.
[12] Sa R, Zhang W, Ge J, et al. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers. J Mol Cell Biol, 2016, 8(3):195-206.
[13] Männistö V, Kaminska D, Kärjä V, et al. Total liver phosphatidylcholine content associates with non-alcoholic steatohepatitis and glycine N-methyltransferase expression. Liver Int, 2019, 39(10):1895-1905.
[14] Liu J, Wang T, He K, et al. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation. Eur Rev Med Pharmacol Sci, 2019, 23(18):8158-8167.
[15] Ma DW, Arendt BM, Hillyer LM, et al. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects. Nutr Diabet, 2016,6(7):220-227.
[16] 路晓茅,张洁,邸阜生.2型糖尿病单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学的变化.中华糖尿病杂志,2020,12(1):41-47.
[17] Montefusco DJ, Allegood JC, Spiegel S, et al. Non-alcoholic fatty liver disease: Insights from sphingolipidomics. Biochem Biophys Res Commun, 2018, 504(3):608-616.
[18] Gorden DL, Myers DS, Ivanova PT, et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res, 2015, 56(3):722-736.
[19] Vergani L. Fattyacids and effects on in vitro and in vivo models of liver steatosis. Curr Med Chem, 2019, 26(19):3439-3456.
[20] 杨蕊旭,胡春秀,宓余强,等.非酒精性脂肪性肝病患者血清脂质组学研究.中华肝脏病杂志,2017,25(2),122-127.

非酒精性单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学比较^*

Serum lipidomics in patients with non-alcoholic simple fatty liver and non-alcoholic steatohepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	闻啟富, 马利军, 王晓亮. 非酒精性脂肪性肝炎患者血清CK18和FGF-21水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 835-838.
[2]	王子璇, 王梦雨, 李经纬, 杨蕊旭, 曾静, 潘勤, 范建高. 门冬氨酸鸟氨酸对非酒精性脂肪性肝炎合并肌少症性肥胖小鼠的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(5): 657-660.
[3]	李妍, 陆伦根, 蔡晓波. HIF-1α对非酒精性脂肪性肝病小鼠肝组织的影响^*[J]. 实用肝脏病杂志, 2021, 24(5): 665-668.
[4]	吴丽蒙, 龚翔, 张燕. 非酒精性脂肪性肝炎患者外周血跨膜蛋白6超家族成员2基因表达与心血管疾病的关系^*[J]. 实用肝脏病杂志, 2021, 24(4): 504-507.
[5]	袁平戈, 陈文雯. 非酒精性脂肪性肝炎新药研发临床思考[J]. 实用肝脏病杂志, 2021, 24(3): 305-307.
[6]	裴旭东, 张晓虎, 褚桂克, 李延玲, 赵萍, 王立坤, 陈新菊. 消脂祛浊方治疗合并肥胖的痰湿型非酒精性单纯性脂肪肝患者临床效果初步研究[J]. 实用肝脏病杂志, 2021, 24(3): 355-358.
[7]	杨振辉, 古宝欢, 戴小灵. 非酒精性脂肪性肝炎患者肝脏受控衰减参数的变化[J]. 实用肝脏病杂志, 2021, 24(2): 212-215.
[8]	吴刚, 陈训军, 张万里, 李芬. 二氢姜黄素体外处理BRL-3A细胞对细胞凋亡通路的影响[J]. 实用肝脏病杂志, 2020, 23(5): 622-625.
[9]	王雨, 王楠, 刘媛媛, 李永勤, 王巧侠, 付建军. 草质素对非酒精性脂肪性肝炎大鼠肝脂肪变和肝内氧化应激的影响[J]. 实用肝脏病杂志, 2020, 23(5): 626-629.
[10]	陈丽丽, 符茂雄, 刘正金, 方其超, 张茂. 非酒精性脂肪性肝炎患者血清成纤维细胞生长因子-21和脂联素水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2020, 23(5): 658-661.
[11]	方菊梅,张万里,陈怡发,刘黎明,黄庆勇. 非酒精性脂肪性肝炎患者血清sCD163和IL-1βmRNA水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2020, 23(3): 368-371.
[12]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[13]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[14]	李梦婷, 李兵航, 周达, 丁永年, 陈源文, 范建高. 非酒精性脂肪性肝病小鼠肝组织脯氨酰内肽酶蛋白及其活性变化^*[J]. 实用肝脏病杂志, 2018, 21(4): 549-552.
[15]	刘晓琳, 信丰智, 杨蕊旭, 赵泽华, 周达, 潘勤, 范建高. 茵栀黄口服液对非酒精性脂肪性肝炎大鼠肝脂肪变的保护作用研究*[J]. 实用肝脏病杂志, 2018, 21(3): 380-383.